




PHARMACEUTICAL 2020

Aclaris Therapeutics Inc.
Rank 285 of 358





PHARMACEUTICAL 2020

Aclaris Therapeutics Inc.
Rank 285 of 358



The relative strengths and weaknesses of Aclaris Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 18% points. The greatest weakness of Aclaris Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is -65%, being 101% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	83,803
Cost of Goods Sold	4,055
Intangible Assets	7,199
Liabilities, Current	22,432
Liabilities, Non-Current	3,736
Other Assets	4,825
Other Compr. Net Income	3.0
Other Expenses	19,175
Other Liabilities	2,217
Other Net Income	-50,296
Other Revenues	4,227
Property and Equipment	2,470
Research and Development	64,899
Selling, General and Administrative Expense	27,156

Output Variable	Value in 1000 USD
Assets	98,297
Liabilities	28,385
Expenses	115,285
Revenues	4,227
Stockholders Equity	69,912
Net Income	-161,354
Comprehensive Net Income	-161,352
Economic Capital Ratio	-65%